China Approves Merck Serono Orphan Drug Kuvan; Paves Way For More Orphan Drug R&D
This article was originally published in PharmAsia News
Executive Summary
China's State FDA has approved Merck Serono's Kuvan (sapropterin) for orphan condition hyperphenylalaninemia in phenylketonuria or BH4 deficiency, a rare congenital metabolic disorder that increases blood phenylalanine levels. The approval underlines opportunities in the Chinese orphan drug market, says a leading Chinese expert
You may also be interested in...
Can Patients Move The Rare Disease Treatment Needle In China?
Innovative orphan drug makers have so far largely shunned China but things could be changing. Chinese patient communities tell the Pink Sheet how they are increasingly taking it upon themselves to lobby regulators and persuade drug developers to include China in their clinical development consideration.
China Orphan Drug Reimbursement: Swift Action Needed – Former Genzyme GM
Only 1% of 5,781 rare diseases in China have effective treatments. Facing reimbursement and infrastructure challenges, the market needs rapid action from government and industry, says Shirley Zhao, former Genzyme China general manager.
China Orphan Drug Reimbursement: Swift Action Needed – Former Genzyme GM
Only 1% of 5,781 rare diseases in China have effective treatments. Facing reimbursement and infrastructure challenges, the market needs rapid action from government and industry, says Shirley Zhao, former Genzyme China general manager.